← SynDRA
RELUGOLIX
SynDRA canonical compound SYN0027346 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | GNRH1 | GNRHR |
|---|
| Mechanism of action | gonadotropin releasing factor hormone receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- GNRHR ANTAGONIST
- Gonadotropin-releasing hormone receptor antagonist
- gonadotropin releasing factor hormone receptor antagonist
Drug classes
- Gonadotropin Releasing Hormone Receptor Antagonists
- Androgen Antagonists
- Hormone Antagonists
- Gonadotropin Releasing Hormone Receptor Antagonist
- P-Glycoprotein Inhibitors
- Cytochrome P450 2B6 Inducers
- Breast Cancer Resistance Protein Inhibitors
- Cytochrome P450 3A Inducers
ATC classes
- L02B · HORMONE ANTAGONISTS AND RELATED AGENTS
- HYPOTHALAMIC HORMONES
Cross-references
Synonyms
- TAK-385
- orgovyx
- relumina
- RVT 601
- Orgovyx
- Relugolix component of myfembree
- TAK 385
- UNII-P76B05O5V6
- CHEMBL1800159
- TAK-385/TAK385
- P76B05O5V6
- 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea
- Relugolix [USAN:INN]
- TAK385
- Relugolix (JAN/INN)
- SCHEMBL778416
- GTPL5586
- DTXSID40224167
- MolPort-044-567-649
- AOMXMOCNKJTRQP-UHFFFAOYSA-N
- EX-A1083
- BCP21587
- ZINC43206033
- BDBM50347982
- AKOS027440398
- SB16721
- DB11853
- CS-5917
- MYFEMBREE COMPONENT RELUGOLIX
- relugolixum
- RefChem:57784
- DTXCID40146658
- C29H27F2N7O5S
- Orgovyx (TN)
- MFCD25976856
- Relugolix (Standard)
- RELUGOLIX [INN]
- RELUGOLIX [JAN]
Reported adverse events
- DVT
- Depression
- Dizziness
- Fatigue
- Headache
- Libido decreased
- Nausea
- Alopecia
- Arthralgia
- Hypersensitivity
- Toothache
- Abnormal uterine bleeding
Look up RELUGOLIX in the interactive SynDRA portal →